{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:16:08Z","timestamp":1787159768403,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2018,3,15]]},"abstract":"<jats:p>Immune\u2010checkpoint inhibitors represent the new standard of care in patients with advanced NSCLC who progressed after first\u2010line treatment. This work aim to assess any difference in both efficacy and safety profiles among Nivolumab, Pembrolizumab and Atezolizumab in pre\u2010treated NSCLC patients. Randomized clinical trials comparing immune\u2010checkpoint inhibitor versus docetaxel in pre\u2010treated patients with advanced NSCLC were included and direct comparison meta\u2010analysis of selected trials have been performed. Subsequently the summary estimates of Nivolumab, Pembrolizumab and Atezolizumab emerging from the direct meta\u2010analysis were selected to provide the pooled estimates of hazard ratio (HR) and relative risk (RR) for the indirect comparisons among these agents. A total of 5 studies met the selection criteria and were included in the meta\u2010analysis. Indirect comparisons for efficacy outcomes showed the RR for ORR nivolumab versus atezolizumab 1.66 (95% CI 1.07\u22122.58), pembrolizumab versus atezolizumab 1.94 (95% CI 1.30\u22122.90). No significant differences in both PFS and OS have been observed. Indirect comparisons for safety showed the RR for G3\u20105 AEs nivolumab versus pembrolizumab 0.41 (95% CI 0.29\u22120.60), nivolumab versus atezolizumab 0.50 (95% CI 0.35\u22120.72). No significant differences in both pneumonitis and discontinuation rate have been observed. The results of this work revealed that nivolumab and pembrolizumab are associated with a significant increase of ORR as compared to atezolizumab and nivolumab is associated with a significant lower incidence of G3\u20105 AEs as compared to the other drugs. These evidences could support the oncologists to select the best drug for each patient.<\/jats:p>","DOI":"10.1002\/ijc.31136","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T04:36:39Z","timestamp":1509165399000},"page":"1277-1284","source":"Crossref","is-referenced-by-count":76,"title":["Looking for the best immune\u2010checkpoint inhibitor in pre\u2010treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab"],"prefix":"10.1002","volume":"142","author":[{"given":"Francesco","family":"Passiglia","sequence":"first","affiliation":[{"name":"Department of Surgical Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Galvano","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Incorvaia","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"List\u00ec","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Bazan","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4370-2008","authenticated-orcid":false,"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3708"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_2_6_4_1","article-title":"Clinical trials of MPDL3280A (anti\u2010PDL1) in patients (pts) with non\u2010small cell lung cancer (NSCLC)","volume":"32","author":"Rizvi NACL","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw326"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7582"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7303.42"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta9260"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1201"},{"key":"e_1_2_6_17_1","unstructured":"BorensteinMHL HigginsJPT RothsteinHR.Introduction to Meta\u2010Analysis. In. Wiley March.2008; ISBN: 978\u20101\u2010119\u201396437\u20107."},{"key":"e_1_2_6_18_1","unstructured":"HigginsJPTGS.Cochrane Handbook for Systematic Reviews of Interventions. In. Wiley\u2010Blackwell. 2011;ISBN 978\u20100\u2010470\u201369951\u20105 (H\/B). Cochrane Community (beta) website. Available at:http:\/\/www.cochrane.org\/handbook."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2010.02.007"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.124"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","unstructured":"SocinskiM CreelanB HornL et al. CheckMate 026: A Phase 3 Trial of Nivolumab vs Investigator's Choice (IC) of Platinum\u2010Based Doublet Chemotherapy (PT\u2010DC) as First\u2010Line Therapy for Stage IV\/Recurrent Programmed Death Ligand 1 (PD\u2010L1)\u2009\u2212\u2009Positive NSCLC. In: Abstract LBA7_PR Presidential Symposium 2 on Sunday 9 October 2016 16:25 to 18:20 (CEST) in Room Copenhagen.","DOI":"10.1093\/annonc\/mdw435.39"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9861"},{"key":"e_1_2_6_25_1","article-title":"Safety and ef fi cacy of MPDL3280A (anti\u2010PDL1) in combination with platinum\u2010based doublet chemotherapy in patients with advanced non\u2010small cell lung cancer (NSCLC)","volume":"33","author":"Liu SPJ","year":"2015","journal-title":"In:J Clin Oncol"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.09.088"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.31136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.31136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:14:50Z","timestamp":1695471290000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.31136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,3,15]]}},"alternative-id":["10.1002\/ijc.31136"],"URL":"https:\/\/doi.org\/10.1002\/ijc.31136","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]}}}